Drug Profile
FR 20950
Latest Information Update: 18 Jul 2002
Price :
$50
*
At a glance
- Originator Fujisawa
- Class Antibacterials; Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 21 Feb 2000 New profile
- 21 Feb 2000 Preclinical development for Bacterial infections in Japan (Unknown route)